Market Analysis & Reporting
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Market Analysis & Reporting
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
Market Analysis & Reporting
Before you continue
The information displayed on The Common Catalyst is provided for informational and educational purposes only. It does not constitute financial, investment, legal, or tax advice, and should not be relied upon as a recommendation to buy, sell, or hold any security or financial product.
By continuing, you acknowledge that you are responsible for your own financial decisions and should consult a qualified professional when appropriate.
29.47
+0.36 (+1.24%)
Latest market quote · 2026-08-07 20:00 (UTC)
Company profile
Healthcare
Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Company websiteIssued common shares
Shares available to trade
Price relative to trailing earnings
Price relative to forecast earnings
Mean published price target
Reported full-time workforce
Shares held by institutions
Shares held by company insiders
Current session activity
High-to-low move
Share of advancing days
Based on daily returns
Versus provisional U.S. equity benchmark
Annualized negative-return risk
Historical one-day loss threshold
Reader research
Join the discussion
Log in to share sentiment, a price target, and your investment thesis.
Log in to commentLargest one-day advance
Largest one-day decline
Largest one-year decline
Low-to-high range position
Shares sold short
Percent of public float
Short-interest ratio
Nearest-expiry open interest
Price, momentum, breadth and range
Scores are technical indicators derived from the available one-year price history and are not investment recommendations. Short-interest and options figures display when supplied by the market-data provider.